The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm

Mohamad Jawhar, Juliana Schwaab, Manja Meggendorfer, Nicole Naumann, Hans-Peter Horny, Karl Sotlar, Torsten Haferlach, Karla Schmitt, Alice Fabarius, Peter Valent, Wolf-Karsten Hofmann, Nicholas C.P. Cross, Georgia Metzgeroth, and Andreas Reiter

Disclosures: H-PH, KS, PV, and AR served as consultants in a global phase-II-study examining the effects of midostaurin in advanced systemic mastocytosis. H-PH, KS, KLS, PV, NCPC and AR received honoraria and/or travel support from Novartis Pharmaceuticals. MJ and JS received travel support from Novartis Pharmaceuticals. TH has equity ownership of the MLL Munich Leukemia Laboratory. MM is employed by the MLL Munich Leukemia Laboratory. The remaining authors declare no competing financial interests.

Contributions: MJ, JS, MM, NN, TH, AF, NCPC, AR performed the laboratory work for the study. MJ, JS, KLS, GM and AR provided patient material and information. HPH and KS reviewed the bone marrow biopsies. MJ, JS, MM, NN, TH, AF, PV, WKH, NCPC, GM and AR wrote the paper.